The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)

A Comparison of Alendronate vs. Alfacalcidol Medication for the Preservation of Bone Mineral Density Around the Femoral Implant and in the Lumbar Spine After a Total Hip Arthroplasty

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01020253

Acronym

ETOD

Enrollment

Registered

2009-11-25

Start date

2006-01-31

Completion date

Unknown

Last updated

2009-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement, Hip, Bone Density

Keywords

bisphosphonate, vitamin D3, Total Hip arthroplasty

Brief summary

The purpose of this study is to evaluate whether alendronate and alfacalcidol are effective on prosthetic or lumbar spine BMD after total hip arthroplasty.

Interventions

DRUGalendronate, alfacalcidol

Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

44 Years to 82 Years

Healthy volunteers

Inclusion criteria

* osteoarthritis of the hip * patients after total hip arthroplasty

Exclusion criteria

* diseases related to bone metabolism * patients taking drugs which affect bone metabolism

Design outcomes

Primary

Measure	Time frame
DEXA QDR 2000, Hologic Co.	1, 12, 24 and 48 weeks after operation

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026